Dr Reddys Laboratories

Dr Reddy's Laboratories, a pharmaceutical preparation manufacturer headquartered in India, has reported significant carbon emissions across its operations. For the reporting year 2025, the company's total emissions were approximately 1.29 billion kg CO2e, comprising 142.77 million kg CO2e from Scope 1, 94.69 million kg CO2e from Scope 2 (market-based), and 845.85 million kg CO2e from Scope 3. This marks a decrease from the previous year, with total emissions in 2024 estimated at approximately 1.17 billion kg CO2e. In 2023, total emissions stood at approximately 1.27 billion kg CO2e, including 214.26 million kg CO2e from Scope 1, 137.63 million kg CO2e from Scope 2, and 921.06 million kg CO2e from Scope 3.

The company has set ambitious climate targets. By 2030, Dr Reddy's Laboratories aims for 100% renewable power. Furthermore, they have committed to reducing Scope 1 and 2 greenhouse gas (GHG) emissions by 50.2% per million USD revenue by FY2031, based on a FY2021 baseline. This is equivalent to a 25% absolute reduction.

In line with Science Based Targets initiative (SBTi) commitments, Dr Reddy's Laboratories aims for further reductions. They are committed to reducing absolute Scope 1 and 2 GHG emissions by 80.0% by FY2030 from a FY2023 base year. Concurrently, they aim for a 90.0% absolute reduction in Scope 1 and 2 GHG emissions by FY2045. The company also pledges to achieve net-zero greenhouse gas emissions across its entire value chain by FY2045. For Scope 3 emissions, Dr Reddy's Laboratories is targeting an absolute reduction of 12.3% by FY2031 from a FY2021 base year. More recently, a near-term target of 51.6% reduction in Scope 3 GHG emissions per INR value added by FY2030 has been set, alongside a long-term goal of reducing Scope 3 emissions by 90.0% by FY2045.